DK2040548T3 - Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase - Google Patents
Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidaseInfo
- Publication number
- DK2040548T3 DK2040548T3 DK07812295T DK07812295T DK2040548T3 DK 2040548 T3 DK2040548 T3 DK 2040548T3 DK 07812295 T DK07812295 T DK 07812295T DK 07812295 T DK07812295 T DK 07812295T DK 2040548 T3 DK2040548 T3 DK 2040548T3
- Authority
- DK
- Denmark
- Prior art keywords
- glucocerebrosidase
- activity
- increasing
- beta
- neurological disorders
- Prior art date
Links
- 102000004547 Glucosylceramidase Human genes 0.000 title abstract 7
- 108010017544 Glucosylceramidase Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81595206P | 2006-06-23 | 2006-06-23 | |
| PCT/US2007/072016 WO2007150064A2 (en) | 2006-06-23 | 2007-06-25 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2040548T3 true DK2040548T3 (da) | 2012-08-13 |
Family
ID=38834440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07812295T DK2040548T3 (da) | 2006-06-23 | 2007-06-25 | Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7829579B2 (da) |
| EP (1) | EP2040548B1 (da) |
| JP (1) | JP5303458B2 (da) |
| KR (1) | KR101402554B1 (da) |
| AT (1) | ATE555788T1 (da) |
| AU (1) | AU2007260812B2 (da) |
| BR (1) | BRPI0713442A2 (da) |
| CA (1) | CA2656643C (da) |
| DK (1) | DK2040548T3 (da) |
| ES (1) | ES2387845T3 (da) |
| IL (1) | IL196151A (da) |
| MX (1) | MX2009000032A (da) |
| PT (1) | PT2040548E (da) |
| WO (1) | WO2007150064A2 (da) |
| ZA (1) | ZA200900270B (da) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| EP2040548B1 (en) | 2006-06-23 | 2012-05-02 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of beta -glucocerebrosidase |
| GB0622702D0 (en) * | 2006-11-15 | 2006-12-27 | Univ Dundee | Selective glycosidase inhibitors |
| HUE027278T2 (en) | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| CA2728363C (en) * | 2008-06-26 | 2019-02-19 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
| CA2745451A1 (en) * | 2008-11-14 | 2010-05-20 | Parkinson's Institute | Compositions and methods for the treatment of altered a-synuclein function |
| NZ595629A (en) * | 2009-04-09 | 2013-04-26 | Amicus Therapeutics Inc | Methods for preventing and/or treating lysosomal storage disorders |
| WO2010118282A1 (en) * | 2009-04-09 | 2010-10-14 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| GB0906159D0 (en) * | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
| ES2585584T3 (es) * | 2009-05-26 | 2016-10-06 | Amicus Therapeutics, Inc. | Utilización de chaperonas farmacológicas para mejorar la fabricación y la purificación de ß-glucosidasa ácida |
| US9206457B2 (en) * | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| PL3354277T3 (pl) * | 2009-07-28 | 2021-12-13 | Takeda Pharmaceutical Company Limited | Kompozycje i sposoby leczenia choroby gauchera |
| PL2490712T3 (pl) | 2009-10-19 | 2015-12-31 | Amicus Therapeutics Inc | Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz |
| KR101769396B1 (ko) * | 2009-10-19 | 2017-08-18 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| MX337933B (es) * | 2009-10-19 | 2016-03-29 | Amicus Therapeutics Inc | Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal. |
| PL2646044T3 (pl) | 2010-11-30 | 2020-03-31 | Orphazyme A/S | Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70 |
| US9556166B2 (en) | 2011-05-12 | 2017-01-31 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| EP2533051A1 (en) | 2011-06-06 | 2012-12-12 | Centogene GmbH | Method for the diagnosis of Gaucher's disease |
| US9845327B2 (en) | 2011-06-22 | 2017-12-19 | The General Hospital Corporation | Treatment of proteinopathies |
| WO2013112651A2 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| BR112015009746A2 (pt) * | 2012-11-05 | 2017-08-15 | Genzyme Corp | Agente que aumenta atividade de glicocerebrosidase em mamíferos |
| US9750712B2 (en) * | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| JP2017502961A (ja) | 2013-12-23 | 2017-01-26 | アレクトス セラピューティックス インコーポレイテッド | グルコセレブロシダーゼモジュレーターおよびその使用 |
| US9675627B2 (en) | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| JP6678676B2 (ja) | 2014-09-15 | 2020-04-08 | オーファザイム エー/エス | アリモクロモル製剤 |
| KR102662215B1 (ko) | 2014-11-06 | 2024-05-02 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 |
| AU2016256895B2 (en) | 2015-05-07 | 2022-05-26 | Takeda Pharmaceutical Company Limited | Glucocerebrosidase gene therapy for parkinson's disease |
| CA3020310A1 (en) * | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR20230104752A9 (ko) | 2016-04-06 | 2024-11-15 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물및 의학적 장애의 치료에서의 그의 용도 |
| US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| BR112018070653A2 (pt) | 2016-04-29 | 2019-02-05 | Orphazyme As | ingrediente farmacêutico ativo, e, composição |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル-アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ[1,2-b]ピリダジン、置換イミダゾ[1,5-b]ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
| EA202091032A1 (ru) * | 2017-10-26 | 2020-07-17 | Шайр Хьюман Дженетик Терапиз, Инк. | Составы, содержащие глюкоцереброзидазу и изофагомин |
| CN108428452B (zh) | 2018-03-14 | 2019-12-13 | 百度在线网络技术(北京)有限公司 | 终端支架和远场语音交互系统 |
| EP3814336A1 (en) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| CR20200652A (es) | 2018-06-27 | 2021-04-28 | Proteostasis Therapeutics Inc | Compuestos que aumentan la actividad del proteosoma |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| BR112021010793A2 (pt) * | 2018-12-05 | 2021-10-13 | Washington University | Métodos de detecção, prevenção, reversão e tratamento de doenças neurológicas |
| EP3959196A4 (en) | 2019-04-25 | 2023-04-12 | Takeda Pharmaceutical Company Limited | ISOFAGOMIN SALTS, METHODS OF USE AND FORMULATIONS |
| CN111450306B (zh) * | 2020-03-06 | 2021-11-19 | 大连理工大学 | 外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法 |
| AU2021380947C1 (en) | 2020-11-19 | 2025-02-20 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
| EP4329881A4 (en) * | 2021-04-30 | 2025-06-11 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2134749T3 (es) * | 1996-10-15 | 2005-03-16 | D-Gen Limited | Diagnostico de la encefalopatia espongiforme. |
| GB2333362B (en) | 1996-10-15 | 2001-05-16 | Imperial College | Typing and diagnosis of spongiform encephalopathy |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| WO2004069190A2 (en) * | 2003-01-31 | 2004-08-19 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
| CN1901907A (zh) | 2003-11-12 | 2007-01-24 | 阿米库斯治疗学公司 | 用于治疗戈谢病的葡糖并咪唑和多羟基环己烯基胺衍生物 |
| CN104771402A (zh) | 2005-06-08 | 2015-07-15 | 阿米库斯治疗学公司 | 溶酶体酶编码基因突变相关的cns紊乱的治疗 |
| PT1860101E (pt) * | 2006-05-24 | 2011-07-12 | Amicus Therapeutics Inc | Sal de tartrato da isofagomina e métodos de uso |
| EP2040548B1 (en) | 2006-06-23 | 2012-05-02 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of beta -glucocerebrosidase |
| KR20100017879A (ko) | 2007-05-22 | 2010-02-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 이소파고민과 이의 유도체를 제조하는 새로운 방법 |
-
2007
- 2007-06-25 EP EP20070812295 patent/EP2040548B1/en active Active
- 2007-06-25 PT PT07812295T patent/PT2040548E/pt unknown
- 2007-06-25 DK DK07812295T patent/DK2040548T3/da active
- 2007-06-25 KR KR1020097001465A patent/KR101402554B1/ko not_active Expired - Fee Related
- 2007-06-25 WO PCT/US2007/072016 patent/WO2007150064A2/en not_active Ceased
- 2007-06-25 CA CA2656643A patent/CA2656643C/en not_active Expired - Fee Related
- 2007-06-25 AU AU2007260812A patent/AU2007260812B2/en active Active
- 2007-06-25 AT AT07812295T patent/ATE555788T1/de active
- 2007-06-25 JP JP2009518489A patent/JP5303458B2/ja active Active
- 2007-06-25 BR BRPI0713442-8A patent/BRPI0713442A2/pt not_active Application Discontinuation
- 2007-06-25 MX MX2009000032A patent/MX2009000032A/es active IP Right Grant
- 2007-06-25 ES ES07812295T patent/ES2387845T3/es active Active
- 2007-06-25 US US11/768,043 patent/US7829579B2/en active Active
-
2008
- 2008-12-23 IL IL196151A patent/IL196151A/en active IP Right Grant
-
2009
- 2009-01-13 ZA ZA2009/00270A patent/ZA200900270B/en unknown
-
2010
- 2010-11-08 US US12/941,468 patent/US9119845B2/en active Active
-
2014
- 2014-08-26 US US14/469,008 patent/US9402837B2/en active Active
-
2016
- 2016-08-01 US US15/225,029 patent/US10064851B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2656643C (en) | 2015-08-25 |
| ATE555788T1 (de) | 2012-05-15 |
| US20150025109A1 (en) | 2015-01-22 |
| WO2007150064A3 (en) | 2008-02-21 |
| BRPI0713442A2 (pt) | 2012-03-06 |
| WO2007150064A2 (en) | 2007-12-27 |
| MX2009000032A (es) | 2009-01-23 |
| US20170027919A1 (en) | 2017-02-02 |
| US7829579B2 (en) | 2010-11-09 |
| KR101402554B1 (ko) | 2014-06-19 |
| JP2009541489A (ja) | 2009-11-26 |
| US10064851B2 (en) | 2018-09-04 |
| IL196151A (en) | 2015-08-31 |
| EP2040548A4 (en) | 2009-12-23 |
| AU2007260812B2 (en) | 2012-08-16 |
| CA2656643A1 (en) | 2007-12-27 |
| AU2007260812A1 (en) | 2007-12-27 |
| PT2040548E (pt) | 2012-08-02 |
| US20080009516A1 (en) | 2008-01-10 |
| EP2040548B1 (en) | 2012-05-02 |
| ZA200900270B (en) | 2011-02-23 |
| US9402837B2 (en) | 2016-08-02 |
| KR20090021393A (ko) | 2009-03-03 |
| IL196151A0 (en) | 2009-11-18 |
| ES2387845T3 (es) | 2012-10-02 |
| EP2040548A2 (en) | 2009-04-01 |
| JP5303458B2 (ja) | 2013-10-02 |
| US9119845B2 (en) | 2015-09-01 |
| US20110052613A1 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2040548T3 (da) | Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase | |
| MX2020011747A (es) | Terapias genicas para los trastornos lisosomales. | |
| MX2021012184A (es) | Terapias genicas para trastornos lisosomales. | |
| AU2018253615A1 (en) | Adeno-associated virus mediated gene transfer to the central nervous system | |
| CY1108927T1 (el) | Αναστολεις μιτωτικης κινεσινης | |
| NO20092150L (no) | Fremgangsmater for behandling av hyperkolesterolemi | |
| MX389903B (es) | Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal. | |
| MX354776B (es) | Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal. | |
| MX2015011943A (es) | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. | |
| WO2008073919A3 (en) | Mir-20 regulated genes and pathways as targets for therapeutic intervention | |
| MX339820B (es) | Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1. | |
| MX2010009767A (es) | Uso de celulas madre mesenquimales para tratar trastornos y enfermedades geneticas. | |
| AU2007257423A8 (en) | Purine analogs | |
| NO20050198L (no) | Mitotiske kinesininhibitorer | |
| MX366774B (es) | Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1. | |
| WO2008073920A3 (en) | Mir-21 regulated genes and pathways as targets for therapeutic intervention | |
| MX2010003371A (es) | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. | |
| NZ718173A (en) | Clostridium histolyticum enzymes and methods for the use thereof | |
| WO2010017436A3 (en) | Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides | |
| SG170819A1 (en) | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith | |
| AU2009279857A8 (en) | Modulation of toll-like receptor 3 expression by antisense oligonucleotides | |
| MX2023001562A (es) | Terapias genicas para trastornos lisosomales. | |
| IN2013DN11328A (da) | ||
| MX2009008846A (es) | Dispositivo de seguridad. | |
| MX2011012596A (es) | Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos. |